Zhittya Genesis Medicine Announces: Parkinson’s Disease Sufferers Motor Skills Improved by 50% After Medical Research Study
June 16, 2022 14:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, June 16, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that the human test subjects in its first-in-human research study for the...
Global Autologous Cell Therapy Product Market ($ 34.8 Bn by 2028) Growth Forecast at 17.1% CAGR During 2022 to 2028 COVID-19 Impact and Global Analysis by Vantage Market Research
March 04, 2022 03:40 ET
|
Vantage Market Research
WASHINGTON, March 04, 2022 (GLOBE NEWSWIRE) -- Recently, the Autologous Cell Therapy Product Market is changing the face of the medicinal treatment and therapeutics. The major factors driving the...
Sunshine Biopharma Expands Board of Directors
November 03, 2021 12:35 ET
|
Sunshine Biopharma Inc.
MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
October 06, 2021 08:00 ET
|
Sunshine Biopharma Inc.
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
June 07, 2021 07:00 ET
|
Spinogenix, Inc.
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system disorders...
Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board
April 20, 2021 11:31 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, April 20, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage...
Cognition Therapeutics Publishes Biomarker Findings from Clinical Study of CT1812 Supporting Positive Impact on Synapse Biology
February 10, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology
February 01, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Intelligent Drug Discovery Market Size To Be Worth USD 3,711.8 Million by 2027 | Emergen Research
December 09, 2020 13:00 ET
|
Emergen Research
Vancouver, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- The Global Intelligent Drug Discovery Market is forecast to be worth USD 3,711.8 Million by 2027, according to a current analysis by...
Neurodegenerative Diseases Drugs Market Expands at 7.2% CAGR and Hit USD 62,786.2 Million by 2026; Biogen and F. Hoffmann-La Roche Ltd Cover More than Half of the Share: Fortune Business Insights
November 12, 2020 02:52 ET
|
Fortune Business Insights
Pune, Nov. 12, 2020 (GLOBE NEWSWIRE) -- The global neurodegenerative diseases drugs market size is expected to derive growth from the rising prevalence of neurodegenerative diseases especially among...